Results 101 to 110 of about 3,401,781 (173)

Preemptive Tocilizumab in CD19 CAR-T Cell Therapy: Evaluating Its Role in Reducing Severe Cytokine Release Syndrome

open access: yes
Objective The purpose of this paper is to explore whether prophylactic use of tocilizumab in patients with B-cell malignancies receiving CD19 Chimeric Antigen Receptor T-cell (CAR-T) therapy reduces the incidence of severe Cytokine Release Syndrome (CRS)
Guistolisi, Anna V
core   +1 more source

Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies. [PDF]

open access: yesChin Med J (Engl)
Tu S   +30 more
europepmc   +1 more source

To cytokine release syndrome (CRS) in patients with multiple myeloma (MM): the nursing role

open access: yesHematology & Transfusion International Journal
Sheron Tannara Vargas   +3 more
openaire   +1 more source

Contrasting Two Life-Threatening Syndromes With Similar-Sounding Acronyms: Capillary Leak Syndrome (CLS) and Cytokine Release Syndrome (CRS)

open access: yes
Scientific acronyms help expedite communication but if misheard or misunderstood they can cause confusion and delay life-saving interventions. Such is the case with CRS, cytokine release syndrome and CLS, drug-induced capillary leak syndrome two life ...
Ndje, Amandine P   +1 more
core  

Long-Term Cardiovascular Care After Cytokine Release Syndrome: JACC CardioOncology Primer. [PDF]

open access: yesJACC CardioOncol
Terol B   +6 more
europepmc   +1 more source

A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab

open access: yesA multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Brendan C. Bender   +9 more
openaire   +1 more source

When, Where, and How Much: Toward Smarter Design and Delivery of CAR T‑Cell Therapy. [PDF]

open access: yesACS Bio Med Chem Au
Sathiyamoorthy E   +2 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy